Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551300 | 1.00 | CYSLTR1 (0.45) | CYSLTR1PDE10ACYP1A2CYSLTR2HDAC1 | |
| SCHEMBL11028869 | 1.00 | CYSLTR1 (0.45) | CYSLTR1PDE10ACYP1A2CYSLTR2HDAC1 | |
| SCHEMBL28194971 | 1.00 | CYSLTR1 (0.45) | CYSLTR1PDE10ACYP1A2CYSLTR2HDAC1 | |
| SCHEMBL9186483 | 1.00 | CYSLTR1 (0.45) | CYSLTR1PDE10ACYP1A2CYSLTR2HDAC1 | |
| SCHEMBL1551574 | 1.00 | CYSLTR1 (0.45) | CYSLTR1PDE10ACYP1A2CYSLTR2HDAC1 | |
| SCHEMBL12603937 | 1.00 | CYSLTR1 (0.45) | CYSLTR1PDE10ACYP1A2CYSLTR2HDAC1 | |
| SCHEMBL12603960 | 1.00 | CYSLTR1 (0.45) | CYSLTR1PDE10ACYP1A2CYSLTR2HDAC1 | |
| SCHEMBL9598037 | 0.98 | CYSLTR1 (0.46) | CYSLTR1PDE10ACYP1A2CYSLTR2HDAC1 | |
| SCHEMBL898777 | 0.93 | PDE10A (0.47) | CYSLTR1PDE10ACYP1A2CYSLTR2HDAC1 | |
| Hydrochloric Acid SCHEMBL29127709 | 0.91 | PDE10A (0.46) | CYSLTR1PDE10ACYP1A2CYSLTR2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445511-B2 | Quinoline or quinoxaline derivatives for treating neurodegenerative diseases | Centre National de la Recherche Scientifique (SNRS) (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HCRTR2, HCRTR1, CHRNA2 | CYSLTR1 225/4885PDE10A 2019/4885CYP1A2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.